BTIG analyst Justin Zelin reiterated a Neutral rating on Lyra Therapeutics (NASDAQ: LYRA).The analyst commented: "LYRA reported 3Q25 earnings, with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE